In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Citius Oncology Inc (NASDAQ: CTOR) closed the day trading at $1.11 down -9.02% from the previous closing price of $1.22. In other words, the price has decreased by -$9.02 from its previous closing price. On the day, 2.11 million shares were traded. CTOR stock price reached its highest trading level at $1.23 during the session, while it also had its lowest trading level at $1.07.
Ratios:
For a better understanding of CTOR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.02 and its Current Ratio is at 0.35. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.12.
On November 27, 2024, Maxim Group started tracking the stock assigning a Buy rating and target price of $3.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTOR now has a Market Capitalization of 92699920 and an Enterprise Value of 90791344.
Stock Price History:
The Beta on a monthly basis for CTOR is 3.03, which has changed by -0.15277779 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, CTOR has reached a high of $6.19, while it has fallen to a 52-week low of $0.55. The 50-Day Moving Average of the stock is -29.96%, while the 200-Day Moving Average is calculated to be -27.74%.
Shares Statistics:
Over the past 3-months, CTOR traded about 321.34K shares per day on average, while over the past 10 days, CTOR traded about 855340 shares per day. A total of 71.55M shares are outstanding, with a floating share count of 9.36M. Insiders hold about 88.79% of the company’s shares, while institutions hold 10.01% stake in the company. Shares short for CTOR as of 1763078400 were 240239 with a Short Ratio of 0.75, compared to 1760486400 on 150902. Therefore, it implies a Short% of Shares Outstanding of 240239 and a Short% of Float of 1.38.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Citius Oncology Inc (CTOR) in the stock market.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.33 and -$0.33 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.14, with 1.0 analysts recommending between -$0.14 and -$0.14.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $4.37M. There is a high estimate of $4.37M for the next quarter, whereas the lowest estimate is $4.37M. Based on 1 analysts’ estimates, the company’s revenue will be $62.47M in the next fiscal year. The high estimate is $62.47M and the low estimate is $62.47M.
